— Know what they know.
Not Investment Advice

ADIL NASDAQ

Adial Pharmaceuticals, Inc.
1W: -4.0% 1M: -35.9% 3M: +39.7% YTD: -32.5% 1Y: -56.2% 3Y: -94.3% 5Y: -99.9%
$4.12
-0.01 (-0.24%)
 
Weekly Expected Move ±14.6%
$3 $3 $4 $5 $5
NASDAQ · Healthcare · Biotechnology · Tech Score Sell · Power 35 · $10.8M mcap · 2M float · 14.27% daily turnover · Short 42% of daily vol

Balance Sheet Trends

Total Assets
$7M +32.3% ▲
5Y CAGR: +4.0%
Total Liabilities
$1M +43.1% ▲
5Y CAGR: -1.5%
Shareholders Equity
$5M +29.7% ▲
5Y CAGR: +5.8%
Cash & Investments
$6M +56.8% ▲
5Y CAGR: +6.0%
Total Debt
$0 +0.0% ▲
Net Debt
-$6M -56.8% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$6M$4M$3M$4M$6M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$6M$4M$3M$4M$6M
Net Receivables$0$0$0$0$42K
Inventory$0$0$0$0$0
Other Current Assets$390K$349K$372K$308K$258K
Total Current Assets$6M$5M$3M$4M$6M
Property, Plant & Equip.$304K$244K$4K$0$0
Goodwill & Intangibles$254K$4K$4K$3K$3K
Long-Term Investments$0$0$2M$982K$490K
Other Non-Current Assets$455K$704K-$4K$0$0
Total Non-Current Assets$1M$953K$2M$985K$492K
Total Assets$8M$6M$5M$5M$7M
— Liabilities —
Accounts Payable$286K$276K$127K$250K$655K
Short-Term Debt$50K$0$0$0$0
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$2M$1M$526K$405K$742K
Total Current Liabilities$3M$2M$653K$976K$1M
Long-Term Debt$0$0$0$0$0
Other Non-Current Liab.$1M$492K$0$0$0
Total Non-Current Liabilities$1M$665K$437$0$125K
Total Liabilities$4M$2M$654K$976K$1M
— Equity —
Common Stock$21K$1K$2K$6K$1K
Retained Earnings-$51M-$64M-$69M-$82M-$90M
Accumulated OCI$0$0$0$0$0
Total Stockholders Equity$4M$3M$4M$4M$5M
Total Liabilities & Equity$8M$6M$5M$5M$7M
— Key Metrics —
Total Debt$257K$207K$0$0$0
Net Debt-$6M-$4M-$3M-$4M-$6M
Total Investments$0$0$2M$982K$490K

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms